- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 276 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 501 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 380 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 377 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 186 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 152 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 389 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 376 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 282 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 478 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 383 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 216 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 281 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 132 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 474 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 217 Pages
Global
From €5124EUR$5,850USD£4,447GBP

The Liquid Biopsy market within the Pharmaceuticals industry is a rapidly growing field of research and development. It is a minimally invasive procedure that uses a sample of blood to detect and monitor cancer. It is used to detect cancer at an early stage, to monitor the progression of the disease, and to assess the effectiveness of treatments. Liquid biopsy can also be used to detect genetic mutations associated with cancer, which can help guide treatment decisions.
The Liquid Biopsy market is expected to grow significantly in the coming years due to its potential to improve patient outcomes and reduce healthcare costs. It is also expected to benefit from advances in technology, such as the development of more sensitive and specific tests.
Some companies in the Liquid Biopsy market include Guardant Health, Exact Sciences, Biocept, and Genomic Health. Show Less Read more